SCHEMBL424238

SCHEMBL424238

CN(C(=O)n1cnc(-c2ccc(NS(N)(=O)=O)cc2)c1)C1CCCCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.60
CES2 O00748 1/20 0.60
KMT2A Q03164 2/20 0.39
S1PR1 P21453 2/20 0.39
KIF11 P52732 1/20 0.38
TRPV1 Q8NER1 2/20 0.36
TRPA1 O75762 1/20 0.36
MGLL Q99685 1/20 0.36
ATM Q13315 1/20 0.36
RAB9A P51151 1/20 0.36
USP19 O94966 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
LCK P06239 1/20 0.36
HCK P08631 1/20 0.36
SRC P12931 1/20 0.36
KDR P35968 1/20 0.36
POLB P06746 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426004 0.86 FAAH (0.66) FAAHCES2KMT2AS1PR1TRPV1
SCHEMBL425056 0.83 FAAH (0.65) FAAHCES2S1PR1TRPV1TRPA1
SCHEMBL426237 0.83 FAAH (0.45) FAAHCES2KMT2A
SCHEMBL426096 0.83 FAAH (0.67) FAAHCES2KMT2APOLB
SCHEMBL14950289 0.82 FAAH (0.66) FAAHCES2S1PR1TRPV1TRPA1
SCHEMBL425914 0.82 FAAH (0.66) FAAHCES2KMT2AS1PR1TRPV1
SCHEMBL425960 0.81 FAAH (0.62) FAAHCES2S1PR1TRPV1TRPA1
SCHEMBL425807 0.81 FAAH (0.65) FAAHCES2KMT2AS1PR1TRPV1
SCHEMBL425811 0.81 FAAH (0.65) FAAHCES2KMT2AS1PR1TRPV1
SCHEMBL424383 0.81 FAAH (0.74) FAAHCES2KMT2AS1PR1TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CES2 62/4885KMT2A 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.